



Agenus to Report Fourth Quarter and Full Year 2019 Financial Results on March 12, 2020 with Conference Call and Webcast

March 3, 2020

LEXINGTON, Mass., March 3, 2020 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers, today announced it will release its fourth quarter and full year 2019 financial results before the market opens on Thursday, March 12, 2020. Agenus executives will host a conference call and webcast at 8:30 a.m. ET the same day.



Conference Call and Webcast Information:

Date: Thursday, March 12, 2020

Time: 8:30 a.m. ET

Domestic Dial-in Number: 1-844-492-3727 (U.S.)

International Dial-in Number: 1-412-317-5118 (International)

Conference ID: Agenus

The call will also be webcast and will be accessible from the Company's website at <http://investor.agenusbio.com/presentation-webcasts> or via the link: <https://www.webcaster4.com/Webcast/Page/1556/33333>.

A replay will be available on the Company's website approximately two hours after the call.

About Agenus

Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its AgenTus Therapeutics subsidiary), and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and twitter.

Contact:

Agenus Inc.

Regina Grebla, PhD

781-674-4495

Regina.Grebla@agenusbio.com

SOURCE Agenus Inc.